Fertility in male patients with seronegative spondyloarthropathies treated with infliximab - 26/01/13
Corresponding author. Tel.: +30 265 100 7503; fax: +30 265 100 7054.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
The majority of patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are affected during their peak reproductive years. Tumor necrosis factor (TNF)⍺ plays a pivotal role in the pathogenesis of both diseases. Today, anti-TNF⍺ blockers are an essential treatment for these patients. To identify male patients who achieved pregnancy development during their management with anti-TNF⍺ blockers (infliximab).
Methods |
We reviewed the data of 65 patients with AS and 30 patients with PsA who were followed-up in our rheumatology outpatients clinic and they were on infliximab therapy between January 2001 and December 2010.
Results |
We identified overall seven male patients with AS and three male patients with PsA who had fathered 14 healthy infants. Moreover, we recognized one man with PsA who was on infliximab and on concomitant therapy with MTX at the time of conception, whose wife had to proceed to therapeutic abortion due to congenital abnormalities of the fetus (hydrocephalia), while she was on the first trimester of pregnancy.
Conclusions |
We described male patients with AS and PsA who demonstrated no fertility problems while they were on infliximab treatment. The data designated in this report provide some supportive evidence for the safe use of infliximab in male patients who are affected of those inflammatory diseases during their peak reproductive years.
Le texte complet de cet article est disponible en PDF.Keywords : Spondyloarthropathies, Ankylosing spondylitis, Psoriatic arthritis, Infliximab, Male fertility
Plan
Vol 80 - N° 1
P. 34-37 - janvier 2013 Retour au numéro
Article précédent
- Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis
- Sabrina Dadoun, Nadine Zeboulon-Ktorza, Christophe Combescure, Muriel Elhai, Sylvie Rozenberg, Laure Gossec, Bruno Fautrel
- Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): Correlations with disease activity and severity of joint damage (a multicenter trial)
- Aziza Omar, Ihab Abo-Elyoun, Hanan Hussein, Mohammad Nabih, Hoda Atwa, Suzan Gad, Yasser Emad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?